Northern, WI 06/20/2013 (usastockreport) – The share prices of VIVUS, Inc. (NASDAQ:VVUS) had surged by 3.12 percent to close at $14.19 per share for the end of last trading session on Wednesday. The shares of the company had been trading in the range of $13.74 to $14.90 per during the day, which had pushed the company to hit new peaks. The shares of VIVUS, Inc. (NASDAQ:VVUS) had a market capitalization of $1.43 billion. The stock opened at $14.25 per share.
VIVUS, Inc. (NASDAQ:VVUS) announced that it has filed its definitive proxy materials in connection with the Company’s 2013 Annual Meeting of Stockholders, to be held on July 15, 2013, with the Securities and Exchange Commission (“SEC”). The VIVUS management team has recently gained FDA approval allowing retail pharmacy distribution. Following the launch of Qsymia in September 2012, one of our priorities was to obtain approval of our REMS modification to allow access outside of the restrictive mail-order only channel.
This important milestone was achieved in April 2013. Retail distribution will allow us to broaden the distribution of Qsymia to thousands of certified retail pharmacies, improve patient access to Qsymia, and significantly simplify the prescribing and dispensing process for healthcare providers.
VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil.